Abstract
With evolutionary drug resistance impacting efforts to treat disease, the need for small molecules that exhibit novel molecular mechanisms of action is paramount. In this study, we combined scaffold-directed synthesis with a hybrid experimental and transcriptome analysis to identify bis-spirooxindole cyclopropanes that inhibit cancer cell proliferation through disruption of ribosomal function. These findings demonstrate the value of an integrated, biologically inspired synthesis and assay strategy for the accelerated identification of first-in-class cancer therapeutic candidates.
Keywords:
drug discovery; mechanism of action; natural products; spirooxindoles; transcriptome network.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Cell Proliferation / drug effects
-
Cyclopropanes / chemical synthesis
-
Cyclopropanes / chemistry
-
Cyclopropanes / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Screening Assays, Antitumor
-
Humans
-
Molecular Structure
-
Oxindoles / chemical synthesis
-
Oxindoles / chemistry
-
Oxindoles / pharmacology*
-
RNA, Neoplasm / drug effects*
-
RNA, Neoplasm / genetics
-
RNA, Neoplasm / metabolism
-
Ribosomes / drug effects*
-
Ribosomes / genetics
-
Ribosomes / metabolism
-
Spiro Compounds / chemical synthesis
-
Spiro Compounds / chemistry
-
Spiro Compounds / pharmacology*
-
Structure-Activity Relationship
-
Transcriptome
-
Tumor Cells, Cultured
Substances
-
Antineoplastic Agents
-
Cyclopropanes
-
Oxindoles
-
RNA, Neoplasm
-
Spiro Compounds